CD274 and non-small cell lung carcinoma: Combined measurement of PD-L1 by IHC and RNA-seq may better discern patients who are more or less likely to benefit from checkpoint inhibition, a particular problem for the largest subgroup of NSCLC patients with low PD-L1 expression by IHC and the least certainty of response to checkpoint inhibition.